# A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

> **NCT05432583** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **BioNTech SE** · enrollment: 318 (actual)

## Conditions studied

- Genital Herpes Simplex Type 2

## Interventions

- **BIOLOGICAL:** BNT163
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05432583
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-08
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 318 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05432583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05432583, "A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05432583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*